Analyst picks & changes

Amgen Inc.

(AMGN), Thousand Oaks, Calif.

Cephalon Inc.

(CEPH), West Chester, Penn.

CytoTherapeutics Inc.

(CTII), Providence, R.I.

Regeneron Pharmaceuticals Inc.

(REGN), Tarrytown, N.Y.

Business: Neurological

The failure of Amgen-Regeneron Partners'

BDNF

in Phase III trials for amyotrophic lateral sclerosis (see BioCentury Jan. 13) prompted analysts to revise their outlooks for several companies.

Rodman & Renshaw analyst James Keeney downgraded AMGN to "neutral." While the

Read the full 658 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE